Business
Bioasis Announces Voting Results for 2018 Annual and Special Meeting
Bioasis Announces Voting Results for 2018 Annual and Special Meeting.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n Bioasis \n Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or \n “Bioasis”), a pre-clinical, research-stage biopharmaceutical company \n developing its proprietary xB3 TM platform technology \n for the delivery of therapeutics across the blood-brain barrier (BBB) \n and the treatment of CNS disorders in areas of high unmet medical need, \n including brain cancers and neurodegenerative diseases, today announced \n the voting results from its Annual & Special Meeting held on Mon., Nov. \n 26, 2018 in Toronto, Ontario.\n \n \n Election of Directors\n \n \n All five (5) candidates nominated for election to the Bioasis board of \n directors and listed in the Company's Management Information Circular \n dated Oct. 25, 2018, being Deborah Ann Rathjen, B.Sc. (Hons), Ph.D., \n MAICD, FTSE (chair), Mark Day, Ph.D. (president and chief executive \n officer), Nancy E. Stagliano, Ph.D., John E. Curran and David M. Wurzer, \n were elected.\n \n \n Appointment of Auditors\n \n \n Manning Elliott were reappointed as Bioasis’ auditors.\n \n \n Stock Option Plan\n \n \n A proposed amendment to the Bioasis stock option plan to increase the \n number of common shares issuable under the plan was not approved.\n \n \n On behalf of the Board of Directors of Bioasis Technologies Inc.\n \n \n Mark Day, Ph.D., Director, President & Chief Executive Officer\n \n \n ABOUT BIOASIS\n \n \n Bioasis \n Technologies Inc. is a biopharmaceutical company developing the xB3 \n TM platform, a proprietary technology for the delivery of \n therapeutics across the blood-brain barrier (BBB) and the treatment of \n CNS disorders in areas of high unmet medical need, including brain \n cancers and neurodegenerative diseases. The delivery of therapeutics \n across the BBB represents the final frontier in treating neurological \n disorders. The in-house development programs at Bioasis are designed to \n develop symptomatic and disease-modifying treatments for brain-related \n diseases and disorders. The company maintains headquarters in Guilford, \n Conn., United States. Bioasis trades on the TSX Venture Exchange under \n the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more \n information about the company, please visit www.bioasis.us.\n \n \n ...